東鵬控股(003012.SZ):發明專利"抗菌抗病毒去甲醛防污劑及製備方法、釉面磚及製備方法"榮獲第二十五屆中國專利優秀獎
格隆匯6月8日丨東鵬控股(003012.SZ)公佈,東鵬控股(003012.SZ):近日,國家知識產權局發佈了《關於第二十五屆中國專利獎授獎的決定》(國知發運字〔2025〕20號),公司及控股子公司的發明專利"抗菌抗病毒去甲醛防污劑及製備方法、釉面磚及製備方法"榮獲第二十五屆中國專利優秀獎。此次是公司第四次獲得這一中國專利領域的國家級獎項,彰顯了公司的科技創新實力。
此外,公司及控股子公司於近日取得由國家知識產權局頒發的7項發明專利證書。截至本公告披露日,公司及控股子公司現有各類型有效專利1327項,其中發明專利414項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.